Ginsenoside Rb1 protects against the cardiac toxicity induced by anti-tumor drug vandetanib

Vandetanib is a once-daily oral small molecular tyrosine kinase inhibitor by targeted both vascular endothelial growth factor receptor VEGFR and epidermal growth factor receptor EGFR. Vandetanib is indicated for the treatment of terminal thyroid cancer. Although vandetanib has been reported to induce serious cardiac adverse effects, the exact mechanism remains unknown. The aim of the study is to examine the mechanism and the cardioprotection of ginsenoside Rb1 on vandetanib-induced cardiotoxicity.